Preserved supervised synthesis

Emideltide synthesis · version 1

This URL preserves the exact reviewed public wording and source set for synthesis version 1.

Supervised synthesis

What do selected human studies report about Emideltide?

Manually reviewed September 15, 2026 · version 1

Browse all Human Evidence Reviews · Open preserved synthesis version 1 →

Two selected small studies examined delta sleep-inducing peptide (DSIP) in chronic insomnia. Their short observation periods and incompletely described formulations limit transfer to other preparations or uses.12

Bottom line from this bounded source set

The two reports differ: one described improved sleep and daytime measures, while the other found weak objective changes and no improvement in subjective sleep quality. These small studies do not establish durable benefit or adequately characterize harms.12

Reviewed study record

Chronic insomnia: matched-pairs study

Design

A blinded placebo-controlled parallel-group study used matched pairs and five consecutive laboratory nights.1

Population

Sixteen patients with chronic insomnia participated.1

Outcomes reported

Sleep efficiency and sleep latency differed from placebo, but the authors described the effects as weak and partly attributable to changes in the placebo group. Subjective sleep quality did not improve.1

Limitations

The abstract does not describe random allocation or detailed adverse events. A short, small study cannot establish sustained benefit or uncommon harms.1

Reviewed study record

Chronic insomnia: sleep and daytime performance

Design

A blinded placebo-controlled study observed sleep and daytime performance over seven successive treatment nights.2

Population

Fourteen middle-aged participants with chronic insomnia were studied.2

Outcomes reported

The authors reported improved sleep, alertness and daytime performance, with sleep effects maintained on the first post-treatment night.2

Limitations

The abstract does not clearly describe allocation, the full comparator sequence or adverse events. The findings do not establish longer-term efficacy or safety.2

Reviewed source set

  1. PubMed · 1299794Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. ↗PubMed PMID 1299794 · EFetch XML reviewed 2026-09-15 · payload SHA-256 e55868b51a92e59cb2558e8d45a4b50198227f4332e48d3b6b6eec264fa4cdae
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1159/000118919. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  2. PubMed · 3622582Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. ↗PubMed PMID 3622582 · EFetch XML reviewed 2026-09-15 · payload SHA-256 54e4808c6b14361351f97a08aba706995dee366f53026b2bb9ad54db9be5f9be
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1159/000116143. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗